Fig. 4
From: Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study
Epidemic curves assuming antiviral treatment coverage of 10–100% of eligible symptomatic individuals. Daily new infections assuming no antiviral treatment (Baseline) or assuming coverage of 10–100% of eligible symptomatic individuals in A Kenya, B Mexico, C United States and D Belgium. Here, we assumed an epidemic wave with parameters similar to those of the Omicron epidemic wave (transmissibility, vaccine effectiveness, and vaccination coverage). For each location, each column represents a different value of AVT (25, 50, 75 or 100% reduction in viral load)